Profile data is unavailable for this security.
About the company
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-70.87m
- Incorporated2021
- Employees48.00
- LocationSenti Biosciences Inc2 Corporate Drive, First FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 382-3281
- Fax+1 (302) 655-5049
- Websitehttps://www.sentibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ensysce Biosciences Inc | 4.42m | -7.93m | 8.84m | 7.00 | -- | 1.19 | -- | 2.00 | -2.04 | -2.04 | 0.6545 | 0.498 | 0.7016 | -- | 4.68 | 631,628.60 | -125.79 | -17.68 | -188.13 | -19.42 | -- | -- | -179.29 | -715.78 | -- | -3.88 | 0.0556 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| StimCell Enegetics Inc | 0.00 | -124.17k | 8.92m | 0.00 | -- | -- | -- | -- | -0.0155 | -0.0155 | 0.00 | -- | 0.00 | -- | -- | -- | -299.64 | -703.78 | -- | -- | -- | 84.03 | -- | -2,996.54 | -- | -6.02 | -- | -- | -100.00 | -- | 71.22 | -- | -- | -- |
| Biomx Inc | 0.00 | -8.71m | 8.94m | 58.00 | 1.88 | 0.4644 | -- | -- | 0.2614 | 0.2614 | 0.00 | 2.08 | 0.00 | -- | -- | 0.00 | -18.71 | -- | -24.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Jaguar Health Inc | 10.48m | -37.74m | 9.10m | 49.00 | -- | 0.7539 | -- | 0.8683 | -19.89 | -19.89 | 2.76 | 1.54 | 0.2018 | 0.231 | 7.17 | 213,877.50 | -73.81 | -95.29 | -106.50 | -163.54 | 80.10 | 67.28 | -365.71 | -522.28 | 1.36 | -3.22 | 0.6802 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Yubo International Biotech Ltd | 25.78k | -2.00m | 9.71m | 18.00 | -- | -- | -- | 376.47 | -0.0167 | -0.0167 | 0.0002 | -0.0261 | 0.0145 | 0.0467 | 0.1935 | 1,432.22 | -120.65 | -- | -- | -- | 80.41 | -- | -8,325.41 | -- | 0.1598 | -17,544.82 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -70.87m | 9.71m | 48.00 | -- | 0.608 | -- | -- | -15.59 | -15.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -74.80 | -- | -83.22 | -- | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| BioCardia Inc | 71.00k | -7.72m | 9.79m | 16.00 | -- | 3.51 | -- | 137.85 | -4.22 | -4.22 | 0.036 | 0.6086 | 0.0142 | -- | 1.25 | 4,437.50 | -154.22 | -107.34 | -401.77 | -154.17 | -- | -- | -10,876.06 | -1,779.24 | -- | -- | 0.00 | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 5.55m | 9.93m | 12.00 | 5.41 | 0.3308 | 1.78 | 0.62 | -0.5993 | -0.5993 | 4.89 | 10.01 | 0.5889 | -- | 9.18 | 1,335,000.00 | 20.40 | -70.52 | 22.75 | -81.86 | -- | -- | 34.64 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 377.00k | -6.17m | 10.00m | 11.00 | -- | 1.00 | -- | 26.52 | -0.7135 | -0.7135 | 0.0546 | 1.44 | 0.0266 | -- | 3.69 | 34,272.73 | -43.49 | -192.11 | -53.99 | -329.32 | 79.04 | -- | -1,636.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Imunon Inc | 0.00 | -19.45m | 10.05m | 33.00 | -- | 1.23 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5649 | 0.00 | -- | -- | 0.00 | -99.63 | -50.18 | -137.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Vaccinex Inc | 388.00k | -18.58m | 10.06m | 37.00 | -- | -- | -- | 25.93 | -12.15 | -12.15 | 0.2512 | -0.5081 | 0.1047 | -- | 0.4046 | 10,486.49 | -501.27 | -262.29 | -- | -- | -- | -- | -4,787.89 | -4,257.17 | -- | -49.48 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Dominari Holdings Inc | 12.59m | -22.69m | 10.23m | 26.00 | -- | 0.2673 | -- | 0.8126 | -3.85 | -3.85 | 2.11 | 6.10 | 0.2361 | -- | 3.80 | 484,192.30 | -42.55 | -26.82 | -44.27 | -27.45 | -- | -- | -180.22 | -3,353.52 | -- | -4.83 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.66m | 10.31m | 22.00 | -- | 1.17 | -- | -- | -0.0115 | -0.0115 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -17.29 | -25.03 | -39.98 | -48.76 | -- | -- | -- | -1,692.93 | -- | -0.5009 | 0.614 | -- | -- | -- | -255.12 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 10.46m | 18.00 | -- | 0.1166 | -- | 4.27 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 10.46m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Senti Biosciences Inc's reporting currency: US Dollar USD
8.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Sep 2024 | 176.67k | 3.86% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 97.47k | 2.13% |
| Intel Corp. (Investment Management)as of 30 Sep 2024 | 48.05k | 1.05% |
| Geode Capital Management LLCas of 30 Sep 2024 | 27.29k | 0.60% |
| UBS Securities LLCas of 30 Sep 2024 | 10.50k | 0.23% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.00k | 0.09% |
| Tower Research Capital LLCas of 30 Sep 2024 | 2.36k | 0.05% |
| Harbour Investments, Inc.as of 30 Sep 2024 | 1.50k | 0.03% |
| Sanctuary Advisors LLCas of 30 Jun 2024 | 1.47k | 0.03% |
| Barclays Capital, Inc.as of 30 Sep 2024 | 500.00 | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
